An Open-Label, Multicentre Study to Evaluate the Duration of Clinical Remission of Two Courses of Weekly Intramuscular administration of AMEVIVE (alefacept) by evaluating the time to retreatment with AMEVIVE or an alternative systemic therapy in patients with chronic plaque psoriasis in the context of standard dermatological practice
Phase of Trial: Phase III/IV
Latest Information Update: 21 Jun 2016
At a glance
- Drugs Alefacept (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms MEDRA
- Sponsors Biogen
- 08 Jun 2016 Status changed from active, no longer recruiting to completed.
- 19 Oct 2009 New trial record.